Deep Brain Stimulation for Treatment-Resistant Depression

Helen S. Mayberg,¹,²,* Andres M. Lozano,³,* Valerie Voon,⁴ Heather E. McNeely,⁵ David Seminowicz,⁶ Clement Hamani,³ Jason M. Schwab,³ and Sidney H. Kennedy⁴
¹Rotman Research Institute at Baycrest Centre and Departments of Psychiatry and Neurology University of Toronto Toronto, Ontario, M6A 2E1 Canada
²Emory University School of Medicine Atlanta, Georgia 30322 USA
³Division of Neurosurgery and Toronto Western Hospital Research Institute University Health Network University of Toronto Toronto, Ontario, M5P 2P2 Canada
⁴Department of Psychiatry University Health Network University of Toronto Toronto, Ontario, M5P 2P2 Canada
⁵Neuropsychology Lab Department of Psychiatry Center for Addiction and Mental Health University of Toronto Toronto, Ontario, M5T 1R8 Canada
⁶Rotman Research Institute at Baycrest Centre and the Institute of Medical Science University of Toronto Toronto, Ontario, M6A 2E1 Canada

**Correspondence:** hmayber@emory.edu (H.S.M.); lozano@uhnres.utoronto.ca (A.M.L.)

Introduction

Major depression is the most common of all psychiatric disorders (Wang, 2003). It ranks among the top causes of worldwide disease burden and is the leading source of disability in adults in North America under the age of 50 (World Health Organization, 2001). While depression can be effectively treated in the majority of patients by either medication or some form of evidence-based psychotherapy (American Psychiatric Association, 2000), up to 20% of patients fail to respond to standard interventions (Fava, 2003; Keller et al., 1992). For these patients, trial-and-error combinations of multiple medications and electroconvulsive therapy are often required (Kennedy and Lam, 2003; Lancet UK ECT Review Group, 2003; Sackeim et al., 2001). For patients who remain severely depressed despite these aggressive approaches, new strategies are needed. We describe a strategy directed at this group of treatment-refractory patients with major depression.

Converging clinical, biochemical, neuroimaging, and postmortem evidence suggests that depression is unlikely to be a disease of a single brain region or neurotransmitter system. Rather, it is now generally viewed as a systems-level disorder affecting integrated pathways linking select cortical, subcortical, and limbic sites and their related neurotransmitter and molecular mediators (Manji et al., 2001; Mayberg, 1997; Nemeroff 2002; Nestler et al., 2002; Vaidya and Duman, 2001). While mechanisms driving this “system dysfunction” are not yet characterized, they are likely to be multifactorial, with genetic vulnerability, developmental insults, and environmental stressors all considered important and synergistic contributors (Caspi et al., 2003; Heim et al., 2000; Kendler et al., 2001). Treatments for depression can be similarly viewed within this limbic-cortical system framework, where different modes of treatment modulate specific regional targets, resulting in a variety of complementary, adaptive chemical and molecular changes that re-establish a normal mood state (Vaidya and Duman 2001; Hyman and Nestler, 1996, Mayberg 2003).

Functional neuroimaging studies have had a critical role in characterizing these limbic-cortical pathways (Brody, et al., 2001; Drevets, 1999; Mayberg, 1994, 2003). Our own studies have demonstrated consistent involvement of the subgenual cingulate (Cg25) in both acute sadness and antidepressant treatment effects, suggesting a critical role for this region in modulating negative mood states (Mayberg et al., 1999; Seminowicz et al., 2004). In support of this hypothesis, a decrease in Cg25 activity is reported with clinical response to different antidepressant treatments including specific serotonin reuptake inhibitor (SSRI) antidepressant medications, electroconvulsive therapy (ECT), re-
petitive transcranial magnetic stimulation (rTMS), and ablative surgery (Dougherty et al., 2003; Goldapple et al., 2004; Malizia, 1997; Mayberg et al., 2000; Mottaghy et al., 2002; Nobler et al., 2001).

In addition, Cg25 connections to the brainstem, hypothalamus, and insula have been implicated in the disturbances of circadian regulation associated with depression (sleep, appetite, libido, neuroendocrine changes) (Barbas et al., 2003; Freedman et al., 2000; Jurgens and Muller-Preuss, 1977; Maclean, 1990; Ongur et al., 1998). Reciprocal pathways linking Cg25 to orbitofrontal, medial prefrontal, and various parts of the anterior and posterior cingulate cortices form the neuroanatomical substrates by which primary autonomic and homeostatic processes influence various aspects of learning, memory, motivation and reward—core behaviors altered in depressed patients (Barbas et al., 2003; Carmichael and Price, 1996; Haber, 2003; Vogt and Pandya, 1987).

Recent advances in the surgical treatment of Parkinson's disease have demonstrated that chronic high-frequency deep brain stimulation (DBS) in pathologically overactive brain circuits produces profound clinical benefits (Benabid, 2003; Lang and Lozano, 1998). We have previously shown that clinically effective DBS in the basal ganglia produces both local and remote changes in neural activity as assessed by positron emission tomography (PET) (Davis et al., 1997). We have now leveraged these observations to investigate whether DBS could be used to modulate pathological brain circuits in depression.

We tested the hypothesis that the use of chronic stimulation to modulate Cg25 gray matter and interconnected frontal and subcortical regions could reverse the pathological metabolic activity in these circuits and produce clinical benefits in patients with treatment-resistant depression (TRD). This study reports the use of high-frequency subgenual cingulate white matter (Cg25WM) DBS in six TRD patients.

Results
Patients
All six patients met DSM IV-TR criteria for major depressive disorder (MDD) with a major depressive episode (MDE) of at least 1 year duration diagnosed by structured clinical interview for DSM IV-TR (First et al., 2001), and all had severe depression with a minimum score at entry of 20 on the 17 item Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960). Each met stringent criteria for treatment resistance defined as failure to respond to a minimum of four different antidepressant treatments, including medications, evidence-based psychotherapy, or electroconvulsive therapy, administered at adequate doses and duration during the current episode (Fava, 2003; Sackeim et al., 2001; Thase and Rush 1997). Subjects’ demographic characteristics are presented in Table 1.

Intraoperative Findings
DBS electrodes were implanted in Cg25WM under local anesthesia using MR imaging guidance (Figure 1, row 1: A/B and row 2: C/D) (Schaltenbrand and Wahren, 1977). A protocol similar to that used in evaluating stimulation thresholds for efficacy or adverse effects in patients with Parkinson's disease was adopted for use in these patients (Benabid, 2003; Davis et al., 1997; Lang and Lozano, 1998). The spontaneous report or occurrence of any acute behavioral, cognitive, motor, or autonomic effects was sought during blinded, sequential stimulation of successive, individual contacts (monopolar stimulation, 60 µs pulsewidths, 130 Hz). Voltage was progressively increased up to 9.0 V at each of the eight electrode contacts (four per side), as tolerated. Voltage was increased by approximately 1.0 V every 30 s, with a 15–20 s pause between adjustments, allowing time for patients to identify an effect, if present. Patients reported no motor or sensory phenomena that cued them as to whether current was either on or off.

All patients spontaneously reported acute effects including “sudden calmness or lightness,” “disappearance of the void,” sense of heightened awareness, increased interest, “connectedness,” and sudden brightening of the room, including a description of the sharpening of visual details and intensification of colors in response to electrical stimulation. Reproducible and reversible changes in these phenomena, time locked with stimulation, were observed at specific contacts and parameters for individual patients and not with sham or subthreshold stimulation at those same sites.

Increases in motor speed, volume, and rate of spontaneous speech and improved prosody were observed. In addition, changes in both positive and negative affective rating scores (PANAS scale) (Watson and Clark, 1988) occurred coincident with the patients’ spontaneous statements. There were no overt adverse affective or autonomic changes with stimulation at settings producing these improvements. However, all patients experienced stimulation dose-dependent adverse effects including lightheadedness and psychomotor slowing at high settings (over 7.0 Volts), most often seen at the superior electrode contact.

Postoperative Findings: Short-Term Stimulation Effects
Postoperative MR imaging confirmed the placement of the DBS electrodes within the subgenual cingulate white matter (Cg25WM) bilaterally as targeted. (Figure 1, row 3: E/F). During the 5 day postoperative period, and prior to placement of the pulse generator, daily short sessions of DBS were used to refine final contact selection and stimulation parameters. Systematic testing of individual and paired unilateral and bilateral contacts was performed with a variety of parameters (monopolar [contact anode; case cathode] and bipolar, pulsewidth of 30–250 µs, frequency of 10–130 Hz, progressive increase in voltage from 0.0–9.0 Volts). Acute behavioral changes were again observed during these test sessions. Reproducible improvements in interest, motor speed, activity level, and PANAS scores (reduced negative, increased positive scores) were seen during these stimulation sessions generally using the same contacts and parameters that induced effects in the operating room.

To control for the possibility of a placebo effect, patients were blinded as to which contact was being stim-
Table 1. Patient Demographics

<table>
<thead>
<tr>
<th>Patient #</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>M</td>
<td>F</td>
<td>3F/3M</td>
</tr>
<tr>
<td>Current age</td>
<td>48</td>
<td>59</td>
<td>45</td>
<td>48</td>
<td>37</td>
<td>39</td>
<td>48 ± 9</td>
</tr>
<tr>
<td>Age MDD onset</td>
<td>18</td>
<td>45</td>
<td>21</td>
<td>40</td>
<td>19</td>
<td>34</td>
<td>29.5 ± 12</td>
</tr>
<tr>
<td>Current episode (yrs)</td>
<td>1.5</td>
<td>3</td>
<td>6</td>
<td>8</td>
<td>10</td>
<td>5</td>
<td>5.6 ± 3</td>
</tr>
<tr>
<td># lifetime episodes</td>
<td>12</td>
<td>9</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>4.7 ± 5</td>
</tr>
<tr>
<td>Hamilton depression score (17 item)</td>
<td>29</td>
<td>20</td>
<td>27</td>
<td>24</td>
<td>26</td>
<td>25</td>
<td>25 ± 3</td>
</tr>
<tr>
<td>Past ECT</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>5 of 6</td>
</tr>
<tr>
<td>Past psychotherapy</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>yes</td>
<td>6 of 6</td>
</tr>
<tr>
<td>DSM IV diagnosis</td>
<td>UP</td>
<td>BP II</td>
<td>UP</td>
<td>UP</td>
<td>UP</td>
<td>UP</td>
<td>5 UP</td>
</tr>
<tr>
<td>Melancholic subtype</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>no</td>
<td>yes</td>
<td>yes</td>
<td>4 of 6</td>
</tr>
<tr>
<td>Current medications*</td>
<td>1–5</td>
<td>1, 3</td>
<td>1–4</td>
<td>1, 2, 4, 6, 7</td>
<td>1, 7</td>
<td>1, 4, 5, 7</td>
<td></td>
</tr>
</tbody>
</table>

MDD, major depressive disorder; ECT, electroconvulsive therapy; DSM IV, Diagnostic and Statistical Manual of Mental Disorders, Version IV; UP, unipolar; BP, bipolar.

*Current medications: 1, SSRI/SNRI; 2, bupropion; 3, atypical antipsychotic; 4, benzodiazepine; 5, stimulant; 6, mood stabilizer; 7, other.

...and to the parameter settings. Sham stimulation using either 0.0 Volts or subthreshold stimulation failed to elicit any changes in behavior. Randomized, acute off-on-off-on trials of varying short periods of stimulation (1–5 min) at optimal settings produced consistent stimulation-locked behavioral improvements. Unexpectedly, with application of stimulation for progressively longer periods (from 1 to 3 hr), there was an increasing and correspondingly longer carry-over of the beneficial behavioral effects beyond cessation of the stimulation. These longer stimulation periods were free of adverse effects and were the basis for selecting the stimulation settings used chronically.

Postoperative Selection of Stimulation Parameters

Patients were discharged home with stimulation “off” following implantation of the pulse generators. One week later, chronic DBS was initiated using the lowest voltage and specific electrode contacts that had previously produced acute behavioral effects. Parameters of stimulation were reassessed at weekly intervals with minor adjustments in voltage made to optimize clinical effects. Following a 4 week period of parameter optimization, settings generally remained stable for the remainder of the 6 month follow-up period. The mean stimulation parameters used in this group at 6 months were 4.0 Volts, 60 µs pulsewidths, at a frequency of 130 Hz.

Efficacy of Chronic Bilateral Cg25WM DBS

Standard criteria for antidepressant response and remission were applied (Frank et al., 1991). Response was defined as a decrease in the HDRS-17 score of 50% or greater from the pretreatment baseline; remission as an absolute HDRS-17 score <8. One month postop, two patients met criteria for clinical response (Table 2). By 2 months, five of the six patients met the defined response threshold. Continued antidepressant response was seen in four of these subjects, with some variability up to 5 months. At the 6 month study endpoint, antidepressant response was maintained in four subjects (66%). Moreover, three of these subjects achieved remission or near remission of illness. Consistent with the improvements seen in the HDRS-17 scores, comparable changes were also demonstrated on other quantitative depression scales (see Table 3). Presurgical medications and doses were unchanged throughout the 6 month study.

Normalization of early-morning sleep disturbance (middle insomnia commonly seen in MDD) occurred in the first week of chronic DBS in four of the six subjects (patients 1, 3, 5, and 6) and was the first notable sus-
Table 2. Hamilton Depression Rating Scale, HDRS-17, Scores over Time for Each Subject

<table>
<thead>
<tr>
<th>Time</th>
<th>Hamilton Score(^a)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pt 1(^b)</td>
</tr>
<tr>
<td>Preop baseline</td>
<td>29</td>
</tr>
<tr>
<td>1 week postop (acute stimulation)</td>
<td>5</td>
</tr>
<tr>
<td>2 weeks postop (DBS off)</td>
<td>9</td>
</tr>
<tr>
<td>1 month</td>
<td>10</td>
</tr>
<tr>
<td>2 months</td>
<td>13</td>
</tr>
<tr>
<td>3 months</td>
<td>2</td>
</tr>
<tr>
<td>4 months</td>
<td>4</td>
</tr>
<tr>
<td>5 months</td>
<td>5</td>
</tr>
<tr>
<td>6 months</td>
<td>5</td>
</tr>
</tbody>
</table>

\(^a\)Clinical response: decrease HDRS score >50%. Clinical remission: absolute HDRS score <8.

\(^b\)Clinical responders.

\(^c\)Clinical nonresponders.

Table 3. Psychiatric Ratings: Patient Subgroups

<table>
<thead>
<tr>
<th></th>
<th>All Patients ((n = 6)) Mean Scores (SD)</th>
<th>Responders ((n = 4)) Mean Scores (Range)</th>
<th>Nonresponders ((n = 2)) Mean Scores (Range)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preop 1 mo 3 mo 6 mo</td>
<td>Preop 1 mo 3 mo 6 mo</td>
<td>Preop 1 mo 3 mo 6 mo</td>
</tr>
<tr>
<td>HDRS 17</td>
<td>25.8 (15.8) 12.8 11.5 18.5 15.3 9.3 7.8</td>
<td>23 (22–24) 17 (14–20) 20 (15–25) 19 (15–23)</td>
<td>17 (11–23)</td>
</tr>
<tr>
<td>HDRS 24</td>
<td>34.8 (25.8) 21.2 18.8 15.3 11.3 7.8</td>
<td>33 (32–34) 27 (24–30) 30</td>
<td>30 (27–33) 33 (27–33)</td>
</tr>
<tr>
<td>MADRS</td>
<td>33.3 (18.8) 15.3 11.3</td>
<td>33 (32–34) 27 (24–30)</td>
<td>29 (25–33)</td>
</tr>
<tr>
<td>CGI</td>
<td>6.2 (3.3) 4.2 4.0</td>
<td>6 (4) 6 (3) 6 (3)</td>
<td>6 (6) 6 (6) 6 (6)</td>
</tr>
</tbody>
</table>

Note: f/u MADRAS and HDRS 24 scores not available for patient 6.
Deep Brain Stimulation for Depression

Regional cerebral blood flow changes (CBF PET) in TRD patients at baseline (row 1) and after 3 months (row 2) and 6 months (row 3) of successful treatment with continuous DBS. Sagittal (left) and coronal (right) views. Baseline CBF abnormalities are seen relative to age- and gender-matched healthy control subjects (NC): increases in subgenual cingulate (Cg25) and decrease in dorsolateral prefrontal (F9), ventrolateral prefrontal (F47) and anterior cingulate (Cg24) cortices (row 1, patients 1–5). Three months of DBS relative to baseline (row 2, patients 1, 3, and 5): decreases in Cg25, hypothalamus (Hh), anterior insula (ins), medial frontal (mF10) and orbital frontal (oF11); increases in prefrontal (F9/46), anterior insula and medial frontal cortex (BA10) as well as increases in dorsolateral prefrontal (BA9/46), dorsal anterior (BA24) and posterior cingulate (BA31), premotor (BA6), and parietal (BA40) regions (Table 4; Figure 2, left). A similar pattern of hyperactive Cg25 and hypoactive prefrontal cortex was seen in both the DBS responders and nonresponders (data not shown). Responder versus nonresponder differences at baseline were seen primarily in the magnitude of the prefrontal decreases (responders > nonresponders). Responders also showed an area of hyperactivity in the medial frontal cortex (BA10) not seen in the nonresponders; however, the small sample size precluded further analysis.

The time course of CBF changes with chronic stimulation of Cg25WM was also examined to establish the relationship of regional brain functioning to behavioral effects. Serial scans were performed after 3 and 6 months in four of the first five patients (1, 2, 3, and 5). Group analyses showed local CBF decreases in Cg25 and adjacent orbital frontal cortex (BA11) after 3 months of stimulation. The long-term responders (patients 1, 3, and 5) showed additional CBF changes at both 3 and 6 months: decreases in hypothalamus, anterior insula, and medial frontal cortex (BA10) as well as increases in dorsolateral prefrontal (BA9/46), dorsal anterior (BA24) and posterior cingulate (BA31), premotor (BA6), and parietal (BA40) regions (Table 4; Figure 2, rows 2 and 3). Neither the medial frontal (BA10) decreases nor the dorsal prefrontal (BA9/46), anterior cingulate (BA24), or parietal (BA40) increases were seen in the nonresponder (patient 2) at either 3 or 6 months (data not shown).

The stimulation-induced CBF increases in prefrontal cortex (BA9/46) normalized pretreatment abnormalities. Similarly, the Cg25 decreases not only normalized pretreatment dysfunction, but activity in this region with DBS was actually suppressed below that of the controls at both time points, a change also observed in our previous studies of PET scan changes with response to antidepressant medications (Mayberg et al., 2000). Unlike medication, brainstem changes were not seen early with DBS, although changes in the pons were demonstrated at the 6 month time point. Overall, regional changes seen after 3 months were maintained at 6 months in all three responders (Table 4, middle and right sections).

PET Measures of Regional Blood Flow: Baseline and Treatment Effects

Positron emission tomography was used to characterize the activity in brain networks involved in TRD and to provide a quantitative measure of brain changes associated with stimulation. Baseline, resting-state, cerebral blood flow (CBF) PET scans were performed in the first five study subjects and compared to five age- and sex-matched, nondepressed healthy volunteers. Depressed patients showed a unique pattern of elevated subgenual cingulate (Cg25) blood flow at pretreatment baseline, not previously reported in studies of non-treatment resistant patients. In addition, and consistent with past studies of depressed patients (reviewed in Mayberg, 2003), CBF decreases in prefrontal (BA9/46), premotor (BA6), dorsal anterior cingulate (BA24), and anterior insula were also identified (Figure 2 row 1; Table 4, left). A similar pattern of hyperactive Cg25 and hypoactive prefrontal cortex was seen in both the DBS responders and nonresponders (data not shown). Responder versus nonresponder differences at baseline were seen primarily in the magnitude of the prefrontal decreases (responders > nonresponders). Responders also showed an area of hyperactivity in the medial frontal cortex (BA10) not seen in the nonresponders; however, the small sample size precluded further analysis.

The time course of CBF changes with chronic stimulation of Cg25WM was also examined to establish the relationship of regional brain functioning to behavioral effects. Serial scans were performed after 3 and 6 months in four of the first five patients (1, 2, 3, and 5). Group analyses showed local CBF decreases in Cg25 and adjacent orbital frontal cortex (BA11) after 3 months of stimulation. The long-term responders (patients 1, 3, and 5) showed additional CBF changes at both 3 and 6 months: decreases in hypothalamus, anterior insula, and medial frontal cortex (BA10) as well as increases in dorsolateral prefrontal (BA9/46), dorsal anterior (BA24) and posterior cingulate (BA31), premotor (BA6), and parietal (BA40) regions (Table 4; Figure 2, rows 2 and 3). Neither the medial frontal (BA10) decreases nor the dorsal prefrontal (BA9/46), anterior cingulate (BA24), or parietal (BA40) increases were seen in the nonresponder (patient 2) at either 3 or 6 months (data not shown).

The stimulation-induced CBF increases in prefrontal cortex (BA9/46) normalized pretreatment abnormalities. Similarly, the Cg25 decreases not only normalized pretreatment dysfunction, but activity in this region with DBS was actually suppressed below that of the controls at both time points, a change also observed in our previous studies of PET scan changes with response to antidepressant medications (Mayberg et al., 2000). Unlike medication, brainstem changes were not seen early with DBS, although changes in the pons were demonstrated at the 6 month time point. Overall, regional changes seen after 3 months were maintained at 6 months in all three responders (Table 4, middle and right sections).

Neuropsychological Testing

A comprehensive neuropsychological battery was performed prior to surgery and after 3 and 6 months of stimulation, coincident with the day of the PET scan sessions. The test battery was designed to differentiate dorsolateral, superior medial, and ventrolateral/orbital frontal behaviors, potentially affected by chronic Cg25WM DBS. Serial testing further allowed differentiation between subacute surgical effects, chronic stimulation effects, and correlations with mood change.

At baseline, all patients were functioning intellectually in the average range, consistent with estimates of premorbid IQ. Inspection of results over time indicates that surgery itself did not have a negative impact on general cognition (i.e., IQ, language, basic visual-spatial function). Moreover, many specific areas that were below average or impaired at baseline were significantly improved (or trending due to low power) following 6 months of DBS [responders: visuo-motor function, particularly with the nondominant hand, t(2) = 5.8,
Table 4. PET Blood Flow Changes

<table>
<thead>
<tr>
<th>Region</th>
<th>BA</th>
<th>z Score</th>
<th>x y z Coordinates</th>
<th>Region</th>
<th>BA</th>
<th>z Score</th>
<th>x y z Coordinates</th>
<th>Region</th>
<th>BA</th>
<th>z Score</th>
<th>x y z Coordinates</th>
</tr>
</thead>
<tbody>
<tr>
<td>sgCg</td>
<td>25</td>
<td>↑ 5.16</td>
<td>−10 28 12</td>
<td>sgCg</td>
<td>25</td>
<td>↓ −4.75</td>
<td>−2 8 10</td>
<td>sgCg</td>
<td>25</td>
<td>↓ −3.88</td>
<td>10 20 −4</td>
</tr>
<tr>
<td>Hth</td>
<td></td>
<td>↓ −3.67</td>
<td>0 4 −12</td>
<td>Hth</td>
<td></td>
<td></td>
<td></td>
<td>Hth</td>
<td></td>
<td>↓ −4.63</td>
<td>−2 2 −4</td>
</tr>
<tr>
<td>OrbF</td>
<td>32/10</td>
<td>↓ −5.1</td>
<td>0 34 −8</td>
<td>OrbF</td>
<td>32/11</td>
<td>↓ −4.97</td>
<td>−10 30 −10</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aIns</td>
<td>L</td>
<td>↑ 6.05</td>
<td>−38 22 14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mFr</td>
<td>10</td>
<td>↑ 6.22</td>
<td>26 42 16</td>
<td>mFr</td>
<td>10</td>
<td>↓ −4.19</td>
<td>−22 62 22</td>
<td>mFr</td>
<td>10</td>
<td>↓ −3.53</td>
<td>−14 56 38</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aThal</td>
<td></td>
<td></td>
<td></td>
<td>Caudate</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pCg</td>
<td>31</td>
<td>↑ 4.43</td>
<td>−8 54 26</td>
<td>pCg</td>
<td>31</td>
<td>↑ 4.65</td>
<td>−10 72 20</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DLPF</td>
<td>9</td>
<td>↓ −7.07</td>
<td>−38 28 30</td>
<td>DLPF</td>
<td>9</td>
<td>↑ 4.05</td>
<td>−26 16 30</td>
<td>DLPF</td>
<td>9</td>
<td>↑ 4.63</td>
<td>38 12 34</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VLPF</td>
<td>47</td>
<td>↓ −4.66</td>
<td>−52 42 2</td>
<td>VLPF</td>
<td>46</td>
<td>↑ 4.73</td>
<td>−38 32 18</td>
<td>VLPF</td>
<td>46</td>
<td>↑ 4.13</td>
<td>32 24 10</td>
</tr>
<tr>
<td>dCg</td>
<td>24b</td>
<td>↓ −5.39</td>
<td>−18 28</td>
<td>dCg</td>
<td>24b</td>
<td>↑ 4.06</td>
<td>−10 28</td>
<td>dCg</td>
<td>24b</td>
<td>↑ 3.58</td>
<td>−4 4 34</td>
</tr>
<tr>
<td>PM</td>
<td>6</td>
<td>↑ 4.21</td>
<td>−52 −4 32</td>
<td>PM</td>
<td>6</td>
<td>↑ 3.34</td>
<td>−48 2 22</td>
<td>PM</td>
<td>6</td>
<td>↑ 3.34</td>
<td>−48 2 22</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>R</td>
<td>↑ 5.71</td>
<td>50 0 30</td>
<td>Par</td>
<td>39</td>
<td>↑ 4.13</td>
<td>−36 −56 18</td>
<td>Par</td>
<td>39</td>
<td>↑ 4.01</td>
<td>44 −56 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n. acc</td>
<td>L</td>
<td>↓ −4.68</td>
<td>−4 10 −4</td>
<td>n. acc</td>
<td>L</td>
<td>↓ −4.68</td>
<td>−4 10 −4</td>
<td>n. acc</td>
<td>L</td>
<td>↓ −4.68</td>
<td>−4 10 −4</td>
</tr>
</tbody>
</table>

**a** Patients 1–5 versus five age- and gender-matched healthy controls.

**b** Patients 1, 3, and 5.

**c** SPM t maps. Significance threshold: p < 0.001 uncorrected (t > 3.27); cluster size >50 voxels.

---

p = 0.014; dorsolateral frontal function (verbal fluency), t(2) = 10.0, p = 0.005; ventral prefrontal function (fewer errors on object alternation task), t(2) = 1.7, p = 0.12; and orbital frontal function (fewer risky choices on the gambling task), t(2) = 6.3, p = 0.012). Importantly, there were no acquired impairments in orbital frontal functioning to indicate local DBS adverse effects (Kartsounis et al., 1991; Dalgleish et al., 2004). Nonresponders had normal performance on all tests at baseline, with the exception of slowed psychomotor speed (consistent with effects of depression). Repeat testing was only available for one of these subjects.

**Adverse Events**

Patients 2 and 4 developed local infections related to the connector cable at the chest (patient 2) or scalp (patient 4). Both were treated with intravenous antibiotics. Because of persistent infection in the absence of clinical benefit, the devices were explanted at approximately 6 months with resolution of their infections. No worsening of depressive symptoms was observed in either subject following explantation. Patient 5 developed skin erosion over the hardware and also received antibiotics. While no definitive etiology of these infections was identified, the protocol was modified after patient 5 to implant both the electrodes and pulse generator in a single surgical session, thus eliminating the several-day period where the electrodes remained externalized.

**Discussion**

In this study, we have demonstrated that high-frequency DBS of the Cg25WM can produce striking behavioral changes in patients with TRD. Acute behavioral effects were time locked to stimulation intraoperatively and during short-term testing sessions. Furthermore, sustained clinical improvements decreased with blinded discontinuation of chronic DBS and were re-captured with reinitiation of stimulation, providing evidence as to the specificity of DBS-mediated changes. PET scan data further indicate that Cg25WM DBS has profound effects on the cerebral networks involved in depression and suggest that reversal of baseline abnormalities correlates with antidepressant benefits. While the number of subjects is small, four of six patients (66%) achieved sustained clinical response or remission at the end of 6 months without changes in concurrent medications. This response rate is striking given the extreme treatment refractoriness of this patient population and the well-documented low and poorly sustained placebo response rates of such pa-
The identified CBF change pattern associated with DBS-induced antidepressant effects has important similarities to other therapies for depression. The pattern of reduced activity in the Cg25 and hypothalamus together with prefrontal (BA9) and brainstem increases during DBS are identical to changes reported with antidepressant response to medication (Mayberg et al., 2000). On the other hand, the medial frontal (BA10)/orbital frontal (BA11) decreases and dorsal cingulate (BA24) increases are similar to the change pattern observed with response to cognitive behavioral therapy (Goldapple et al., 2004). The observation that the changes with DBS seen here features both the antidepressant medication and the CBF-induced changes suggests that Cg25WM DBS acts at a critical node of a distributed mood-regulatory network involved in major depression (Mayberg, 2003; Seminowicz et al., 2004).

The baseline pattern of subgenual cingulate hyperactivity in combination with frontal hypoactivity described here in this TRD patient group is a finding that is in contrast to the hypoactivity reported in a more rostral region of subgenual medial prefrontal cortex in familial bipolar and unipolar depressed patients (Drevets et al., 1997). This distinction suggests important differences across subtypes of depression that are potentially relevant to the pathophysiology of major depressive disorders and perhaps their treatment.

Although the mechanisms of action of DBS are incompletely understood, it is clear that stimulation produces both local and remote regional effects (Davis et al. 1997). The behavioral and neuroimaging changes in this study are consistent with suppression of the abnormally elevated baseline Cg25 activity (Figure 2). Possible mechanisms include DBS-activated inhibition of GABAergic afferents and/or high frequency stimulation induced synaptic or metabolic failure (Gabott et al., 1997; Lozano et al., 2002; McIntyre et al., 2004). The remote cortical and brainstem increases could occur as an indirect consequence of trans-synaptic effects in response to decreased activity in Cg25, or direct anterograde or retrograde activation of WM projections coursing through the stimulation field (Barbas et al., 2003; Carmichael and Price, 1996; Haber, 2003; Freedman et al., 2000; Ongur et al., 1998; Jurgens and Muller-Preuss, 1977; Vogt and Pandya, 1987).

In context of these putative mechanisms, the sudden mood change seen with stimulation in the operating room is consistent with an acute deactivation of a hyperactive Cg25, the region immediately adjacent to the area of stimulation. This region has been previously shown to mediate negative mood (increases with sadness, decreases with alleviation of depressive dysphoria) (Mayberg et al., 1999). Early effects of DBS on sleep, energy and motivation also suggest changes in activity of the hypothalamus and brainstem, regions monosynaptically connected to Cg25 (Barbas et al., 2003; Freedman et al., 2000; Jurgens and Muller-Preuss, 1977; Ongur et al., 1998). The more global changes in functioning, i.e., resolution of the depressive syndrome, as well as the prolonged washout time and associated persistent benefit we have observed beyond the cessation of stimulation, may reflect long-term changes in neural network properties as a consequence of prolonged stimulation (Carmichael and Price, 1996; Vaidya and Duman, 2001; Haber, 2003; Vogt and Pandya, 1987). This phenomenon of ongoing benefit after DBS discontinuation has been observed in other disorders targeting different brain circuits, including epilepsy, essential tremor, dystonia, and Parkinson's disease (Hodaie et al. 2002, Kumar et al. 2003; Deep-Brain Stimulation for Parkinson's Disease Study Group, 2001; Vidalhiet et al., 2005).

Despite these encouraging results, there are limitations to this first study of Cg25WM DBS for TRD. Sample size was small, follow-up was limited, and no sham surgery or systematic placebo control arm was used. There was also inadequate power to identify demographic, clinical, subtype, neuropsychological, or imaging markers that might predict response. It may be relevant that all four responders had their first major depressive episode (MDE) before age 35 and had predominant melancholic features whereas the two nonresponders had first episodes in their 40s and had more atypical symptoms (Table 1). Differences in electrode targeting and placement and stimulation parameters may have also contributed to the observed response variance. The relative contribution of these various factors will require testing of additional subjects. In the future, the possible interactions between DBS and antidepressant medications need to be examined.

In conclusion, Cg25WM DBS appears to be efficacious for TRD. The treatment is titratable; there are objective imaging correlates of response effects; and the procedure is well tolerated. This approach may represent an effective, novel intervention for severely disabled patients with treatment-resistant depression.

**Experimental Procedures**

**Patients**

This pilot study included six patients with treatment-resistant major depression, referred by mood disorder specialists (Table 1). The clinical diagnosis of major depressive disorder, major depressive episode (MDD-MDE) was independently confirmed by two psychiatrists and a research coordinator using the Structured Clinical Interview for DSM-IV (First et al., 2001). Patients were selected for surgery because they were resistant to all available therapeutic options. All had failed to respond to a minimum of four different classes of antidepressant medications, prescribed at maximal tolerable doses. Failed treatments included SSRI, venlafaxine, bupropion, monoamine oxidase inhibitor, and tricyclic antidepressants, as well as augmentation strategies using lithium, atypical antipsychotics, and anticonvulsants. Five of the six patients had received electroconvulsive therapy, and all had attempted cognitive behavioral therapy without clinical improvement. Patients with cerebrovascular risk factors or a previous stroke; documented head trauma or neurodegenerative disorders; other Axis I psychiatric diagnoses including schizophrenia, bipolar disorder, panic disorder, obsessive compulsive disorder, or evidence of global cognitive impairment were excluded. Patients with psychotic symptoms, current history of substance abuse, daily use of alcohol in the previous 3 months, or active suicidal ideations were also excluded. Other exclusion criteria included age over 60, pregnancy (risk of radiation exposure from the PET scans), general contraindications for DBS surgery (cardiac pacemaker/defibrillator or other implanted devices), and inability or unwillingness to comply with long-term follow-up. Final selection was made by consensus of the investigator team. Additional subjects were screened but either did
not meet inclusion/exclusion criteria or were accepted but declined.

**Informed Consent Process**

The study protocol was reviewed and approved by three separate ethics committees at the University of Toronto: Toronto Western Hospital, Centre for Addiction and Mental Health, and Baycrest Centre for Geriatric Care. All potential subjects were referred by a psychiatrist that was not involved in the research protocol. They were then seen independently by two psychiatrists (V.V. and S.K.) for diagnostic assessment and if potentially eligible, introductory discussions took place. In all cases, the referring psychiatrist was involved in discussions of the potential benefits and the potential risks associated with DBS. During subsequent meetings with one of the principal investigators (H.S.M.), a family member was invited to attend and did so in all cases. Only after these discussions, were interested candidates referred to the neurosurgical principle investigator (A.L.), who explained the surgical procedure. Interested candidates were offered informed consent forms to read and further discuss as needed. The average time from initial assessment to signing consent was 6–8 weeks.

**Surgery**

The general surgical procedure for the implantation of DBS electrodes has been previously described (Aboisch and Lozano, 2003). A stereotactic frame (Leksell G; Elekta, Inc., Atlanta, GA) was affixed to the patient’s head on the morning of surgery, and preoperative MR images were obtained (Signa, 1.5 tesla; General Electric, Milwaukee, WI). The x, y, and z coordinates of the anterior (AC) and posterior commissures (PC) were determined using axial 3D T1 MR images. To target the subgenual cingulate white matter target, a midline T2 sagittal image was chosen, and the cingulate gyrus below the genu of the corpus callosum was identified (Figure 1, row 1) (Schaltenbrand and Wahren, 1977). A line was traced from the most anterior aspect (genu) of the corpus callosum to the anterior commissure and the midpoint was selected (Figure 1, row 2, left). The T2 coronal section corresponding to the plane of this midpoint was identified, and the coordinates of the transition between the gray and white matters of area 25 were calculated (Figure 1, row 2, right).

In the operating room under local anesthesia, a burr hole was drilled 2 cm from the midline in front of the coronal suture. The underlying dura mater was opened, and the exposed pial surface coagulated. Tisseal (Immuno, Vienna, Austria) was used to prevent cerebrospinal fluid egress and minimize brain shift. The Leksell arc was attached to the head frame and set to the target coordinates. Microrecordings were started 10 mm above the target using electrodes made from parylene-C-insulated tungsten wires and plated with gold and platinum. Tip lengths ranged from 15 to 40 μm and impedances ranged from 0.2 to 1.5 MΩ. Cell activity was amplified (DAM 80 WPI Instruments) with a gain of 1000 and initially filtered to 0.1–10 kHz. The signal was displayed on an oscilloscope and directed to a window discriminator (Winston Electronics) and an audio monitor (Grass AM 8, with noise clipping circuit). In the present study, microelectrode mapping was mainly used to confirm the anatomic location of the gray and white matters of area 25, characterized respectively by the recording of neuronal activity and cell sparse areas. The transition between these two regions was chosen as the final target for the implantation of the electrodes. Final electrode location was confirmed by postoperative MRI (example, Figure 1, row 3).

DBS quadripolar electrodes (Medtronic 3387; Medtronic, Inc., Minneapolis, MN) were implanted bilaterally. Each of the four electrode contacts was tested for adverse effects and clinical benefits. These contacts were numbered from 0 to 3 (right hemisphere) and 4 to 7 (left hemisphere), 0 and 4 being the most ventral and 3 and 7 the most dorsal contacts. The electrodes remained externalized for 5–7 days for clinical testing. They were then connected to a pulse generator (Kineta, Medtronic, Minneapolis, MN) that was implanted in the infraclavicular region under general anesthesia. Prophylactic antibiotics were used for 24 hr after each of the surgical procedures.

**Clinical Evaluation and Follow-Up**

Clinical efficacy was evaluated using standardized ratings by the study psychiatrist blinded to the current stimulus parameters and/or changes. Standardized ratings included the Hamilton Depression Rating Scale (HDRS-17 and 24 item versions) (Frank, et al., 1991), the Montgomery Asberg Depression Scale (MADRS) (Montgomery and Asberg, 1979), the Clinical Global Impressions Scale (CGI) (National Institute of Mental Health, 1970), and the Positive and Negative Affective Scale (PANAS) (Watson and Clark, 1988). Ratings were performed weekly for the first 3 months and biweekly until the study endpoint at 6 months, following baseline assessments at enrollment and 1 week prior to surgery. Medications were unchanged throughout the 6 month follow-up period.

**PET Scanning Acquisition and Data Analysis**

Regional cerebral blood flow PET scans (rCBF) were acquired preoperatively and after 3 and 6 months of chronic DBS (Fox, et al., 1984). Five CBF scans were acquired in each subject at each time point. A comparative scan-set (one time point only) was also acquired under identical scanning conditions in a group of five age- and sex-matched healthy volunteers. All scans were acquired with subjects resting, with eyes closed and no explicit cognitive or motor instructions. Scans were acquired on a GEMS/Scanditronix 2048b camera (15 parallel slices; 6.5 mm center-to-center interslice distance) using measured attenuation correction (BA6Genton and transmission scans). rCBF was measured using the bolus 15O-water technique (35 mCi 15O-water dose/scan; scan duration 60 s) (Mayberg, et al., 1999). Scans were spaced a minimum of 11 min apart to accommodate radioactive decay to background levels. Mood state (sadness and anxiety) was assessed at the end of each scan using a seven-point analog scale and the PANAS to verify behavioral stability over the course of the five scans (Watson and Clark, 1988).

Statistical analyses were performed using SPSS (Wellcome Department of Cognitive Neurology, London, UK) implemented in Matlab (version 5.3, Mathworks Inc., Sherborn, MA). PET scans were first realigned and then spatially normalized into standard three-dimensional space relative to the anterior commissure using the MNI ICBM 152 stereotactic template within SPM99. The images were then corrected for differences in the whole-brain global mean, and smoothed using a Gaussian kernel to a final in-plane resolution of 10 mm at full-width at half maximum. Baseline abnormalities (patients versus controls) and changes with chronic DBS (3 months versus baseline, 6 months versus baseline) were assessed using general linear models (peak voxel threshold p = 0.001; cluster threshold 50 voxels (voxel = 2 mm³) (Worsley, et al., 1996). Resulting t values were lastly converted to z scores for interpretation. Brain locations are reported as x, y, z coordinates in MNI space with approximate Brodmann areas (BA) identified by mathematical transformation of SPM99 coordinates into Talairach space (http://www.mrc-cbu.cam.ac.uk/Imaging/) (Table 3).

**Neuropsychological Testing**

A comprehensive battery of neuropsychological tests was administered at three time points to establish baseline intellectual and cognitive abilities prior to surgery/stimulation and to monitor for changes over time (3 months, 6 months). Tests were chosen to tap general cognitive and intellectual function, as well as four domains of frontal function (Bechera et al., 1994; Friedlaender, et al., 1998; Lang, et al., 1999; Spreen and Strauss, 1998). Parallel versions were used where possible to minimize effects of repetition, and scores are corrected for effects of age, gender, and education, where appropriate. The following tests were administered: Wechsler Adult Intelligence Scale-III; North American Adult Reading Test; Trail Making Tests A and B; Boston Naming Test; Benton Judgment of Line Orientation Test; Hopkins Verbal Learning Test; Brief Visual Spatial Memory Test; Revised; Finger Tapping Test; Grooved Pegboard Test; Controlled Oral Word Association Test; Wisconsin Card Sorting Test; Stroop Color Word Test; Emotional Stroop Task; Object Alternation Test; Iowa Gambling Task; and the International Affective Picture System Ratings. A subset of tests is presented. Paired t tests were used to compare differences between the baseline and 6 months data to determine the probability that the actual mean
difference is consistent with zero. This comparison is aided by the reduction in variance achieved by taking the differences, and thus is a good choice for use with a small sample. A more detailed discussion of neuropsychological results will be published separately.

Supplemental Data
The authors’ conflict of interest statement can be found online at http://www.neuron.org/cgi/content/full/45/5/651/DC1.

Acknowledgments
This study was supported by a distinguished Investigator Award to H.S.M. from the National Alliance for Research in Schizophrenia and Depression (NARSAD). We thank Kari Fulton for patient screening and coordination; Doug Hussey and Alvina Ng for acquisition of the PET studies; Jonathan Dostrovsky and William Hutchison for intraoperative electrophysiological studies; Jean Saint-Cyr for assistance with MR imaging; and Stanley Mayberg and Paul Holzheime for critical review of the manuscript.

References
American Psychiatric Association, A.M. (2000). Practice guideline for the treatment of patients with major depressive disorder (revis-
Dalgleish, T., Yiend, J., Bramham, J., Teasdale, J.D., Ogilvie, A.D., Mahi, G., and Howard, R. (2004). Neuropsychological processing associated with recovery from depression after stereotactic sub-
Fava, M. (2003). Diagnosis and definition of treatment-resistant de-
terview–Research Version (New York: New York Psychiatric Insti-
tute Biometrics Research Department).
tions of area 25 (subgenual cortex) of the macaque monkey. J. Comp. Neurol. 421, 172–188.
Haber, S.N. (2003). The primate basal ganglia: parallel and integ-
ropsychiatry 22, 56–62.
tonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284, 592–597.
lepsy. Epilepsia 43, 603–608.
chiary 152, 151–182.
Lancet UK ECT Review Group (2003). Efficacy and safety of


